Lisa Strovink, MBA, has spent her career working to bring new therapies to market, focused on early-stage health care technology.  Before starting AllerFund, she was the Chief Strategy Officer at the New York Stem Cell Foundation Research Institute. There she oversaw partnerships and strategic operations of the research institute and started and ran their cell therapy programs. These included an early research program on T-Regulatory cells, one of the cell types involved in allergy and autoimmunity.  

Prior to NYSCF, Lisa was a Principal at Ascent Biomedical Partners, a seed and early-stage venture fund, where she evaluated and conducted due diligence on investment opportunities across multiple therapeutic areas.  Lisa previously held a range of strategic and operational roles at Johnson & Johnson including the Director of Strategic Planning for the Medical Devices and Diagnostics group, Director of U.S. Marketing for Cordis Endovascular, and Director of the Carotid Stent Program. One of her roles at J&J was as a Director in a disease-focused fund which invested in pre-clinical and clinical stage products across the pharmaceutical, device, diagnostics and consumer sectors.  Lisa began her career as a management consultant with McKinsey & Company where she advised pharmaceutical and medical device companies and health care providers on strategy, growth and innovation, portfolio management, product launch, and business development, specializing in early-stage technology and market assessment. 

Lisa holds a BA in neurobiology from the University of Pennsylvania (summa cum laude) and an MBA from Harvard Business School. She currently serves on the Memorial Sloan Kettering Technology Development Fund External Review Committee. Lisa is a mother of two boys with food allergies.